Posted on 25. May, 2009 by admin in Library, News
CHVI President Cyndy Nayer is quoted in an article on HartfordBusiness.com, praising an unusual pay-for-performance contract between Cigna and Merck. The deal is this: Cigna gets discounts on Merck diabetes drugs Januvia and Janumet if covered patients take their drugs as prescribed, and even more discounts if patients’ blood sugar drops — on any regimen, not just the Merck-made drugs. Nayer said:
“It’s very significant for the industry. There is a commitment on both sides to improve the
health of the population.”
Read the full story here or download it as a PDF.
Posted on 23. Apr, 2009 by admin in Library, News
This New York Times piece highlights a major step forward by Cigna and Merck:
Merck has agreed to peg what the insurer Cigna pays for the diabetes drugs Januvia and Janumet to how well Type 2 diabetes patients are able to control their blood sugar.
And last week, the two companies that jointly sell the osteoporosis drug Actonel agreed to reimburse the insurer Health Alliance for the costs of treating fractures suffered by patients taking that medicine.
“We’re standing behind our product,” said Dan Hecht, general manager of the North American pharmaceutical business of Procter & Gamble, which sells Actonel with Sanofi-Aventis. “We’re willing to put our money where our mouth is.”
Cigna’s press release quotes CHVI’s Cyndy Nayer:
This alignment is exactly the kind of innovation that supports the ultimate goal of better health for the patient. Our primary goal should be aligning incentives so that the result is a healthier individual. We applaud CIGNA and Merck, and we look for increasing evidence that this kind of thinking can improve the health of our families, our businesses and our communities.
